Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
4.410
+0.060 (1.38%)
At close: Oct 8, 2025, 4:00 PM EDT
4.470
+0.060 (1.36%)
After-hours: Oct 8, 2025, 6:27 PM EDT
Veru Inc. Revenue
Veru Inc. had revenue of $16.89M in the twelve months ending June 30, 2025, up 337.24% year-over-year. In the fiscal year ending September 30, 2024, Veru Inc. had annual revenue of $16.89M with 3.62% growth.
Revenue (ttm)
$16.89M
Revenue Growth
+337.24%
P/S Ratio
3.77
Revenue / Employee
$80,412
Employees
210
Market Cap
64.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 16.89M | 589.46K | 3.62% |
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VERU News
- 15 days ago - Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity - GlobeNewsWire
- 2 months ago - Veru Inc. (VERU) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewsWire
- 2 months ago - Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study - GlobeNewsWire
- 2 months ago - Veru Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - Veru to Participate in the 2025 BTIG Virtual Biotech Conference - GlobeNewsWire
- 4 months ago - Veru to Participate in the Virtual BTIG Obesity Health Forum - GlobeNewsWire
- 4 months ago - Veru's Enobosarm Shows Muscle In Wegovy Combo Trial - Benzinga